EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Comparable Neutralizing Antibody Responses Following JN.1 and KP.2‐Based COVID‐19 Vaccination Suggest Limited Added Value of Minor Strain Updates: A Multicentre Immunogenicity Study

Lena Pracher, Mastura Wahedi, Anselm Jorda iD, Michelle M Fukumitsu, Marlene Prager, Dragan Copic, Jasmin Zessner-Spitzenberg, Edith Lackner, Theresa Pecho, Katie Sharff, Justin Iampietro, Joshua Nealon und 3 weitere

Influenza and Other Respiratory Viruses · 2026-06 · 20 (6)

DOI: 10.1111/irv.70268 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Influenza and Other Respiratory Viruses, online erschienen am 09.06.2026. Verfasst von Lena Pracher und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, Antibodies, Viral, COVID-19 Vaccines, SARS-CoV-2. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

COVID‐19 vaccines are periodically updated to address SARS‐CoV‐2 evolution. Whether minor antigen changes provide immunological or even clinical benefit remains unclear. This study compared neutralizing antibody responses following vaccination with the JN.1‐based or KP.2‐based 2024/25 Pfizer‐BioNTech mRNA vaccine.

Methods

Adults aged 18–64 years who received the JN.1 vaccine in Austria, or the KP.2 vaccine in the United States were enrolled. A single blood sample was obtained within 120 days post‐vaccination. Pseudovirus neutralization assays against SARS‐CoV‐2 variants XBB.1.5, JN.1, KP.2, KP3.1.1, XEC and LP.8.1 were performed. Geometric mean titre (GMT) ratios were analysed using t‐tests and multivariable regression adjusted for age, sex, vaccination intervals, and prior infection.

Results

Among 191 participants (78 JN.1, 113 KP.2), GMTs (95% CI) for XBB.1.5 variant were higher in the JN.1 cohort (3498 [2535–4826]) than in the KP.2 cohort (1901 [1386–2607]), GMT ratio 1.84 (1.16–2.92). For the JN.1 variant, GMTs were 1122 (819–1538) in the JN.1 cohort and 695 (510–948) in the KP.2 cohort (GMT ratio: 1.61 [1.03–2.54]). GMTs for other variants did not differ significantly. After adjustment, only the XBB.1.5 difference remained significant ( p = 0.04).

Conclusions

Comparable neutralizing responses across JN.1 lineage variants suggest that annual COVID‐19 strain updates targeting variants with small differences within the same antigenic cluster may have limited impact on vaccine‐induced protection. These findings may inform future public health policy and regulatory decision‐making for COVID‐19 vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSARS-CoV-2COVID-19Immunogenicity, VaccineHumansAdultFemaleMiddle AgedMaleYoung AdultAdolescentUnited StatesAustriaVaccination

Substanzen

Antibodies, NeutralizingAntibodies, ViralCOVID-19 Vaccines

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
  • Department of Occupational Health, Oregon Health and Science University, Portland, Oregon, USA.
  • Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Division of Nephrology and Dialysis, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Sanofi Vaccines, Waltham, Massachusetts, USA.

ORCID-Profile: Anselm Jorda

Förderung

  • Sanofi

Zitieren

APA

Pracher, L., Wahedi, M., Jorda, A., Fukumitsu, M. M., Prager, M., Copic, D., Zessner-Spitzenberg, J., Lackner, E., Pecho, T., Sharff, K., Iampietro, J., Nealon, J., Messer, W. B., Zeitlinger, M., & Curlin, M. E. (2026). Comparable Neutralizing Antibody Responses Following JN.1 and KP.2‐Based COVID‐19 Vaccination Suggest Limited Added Value of Minor Strain Updates: A Multicentre Immunogenicity Study. Influenza and Other Respiratory Viruses, 20(6). https://doi.org/10.1111/irv.70268

Vancouver

Pracher L, Wahedi M, Jorda A, Fukumitsu MM, Prager M, Copic D, et al. Comparable Neutralizing Antibody Responses Following JN.1 and KP.2‐Based COVID‐19 Vaccination Suggest Limited Added Value of Minor Strain Updates: A Multicentre Immunogenicity Study. Influenza and Other Respiratory Viruses. 2026;20(6). doi:10.1111/irv.70268

BibTeX
@article{Pracher2026,
  author = {Pracher, Lena and Wahedi, Mastura and Jorda, Anselm and Fukumitsu, Michelle M and Prager, Marlene and Copic, Dragan and Zessner-Spitzenberg, Jasmin and Lackner, Edith and Pecho, Theresa and Sharff, Katie and Iampietro, Justin and Nealon, Joshua and Messer, William B and Zeitlinger, Markus and Curlin, Marcel E},
  title = {Comparable Neutralizing Antibody Responses Following JN.1 and KP.2‐Based COVID‐19 Vaccination Suggest Limited Added Value of Minor Strain Updates: A Multicentre Immunogenicity Study},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2026},
  volume = {20},
  number = {6},
  doi = {10.1111/irv.70268}
}
Kostenlos starten →